American Financial Group Inc. Maintains Position in Omeros Corporation (OMER)
American Financial Group Inc. maintained its stake in Omeros Corporation (NASDAQ:OMER) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 715,101 shares of the biopharmaceutical company’s stock at the end of the third quarter. American Financial Group Inc. owned approximately 1.82% of Omeros Corporation worth $7,980,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in OMER. Wedbush Securities Inc. boosted its stake in shares of Omeros Corporation by 8.6% in the third quarter. Wedbush Securities Inc. now owns 92,635 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 7,372 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Omeros Corporation by 30.6% in the third quarter. UBS Asset Management Americas Inc. now owns 48,316 shares of the biopharmaceutical company’s stock worth $539,000 after buying an additional 11,311 shares in the last quarter. Ingalls & Snyder LLC boosted its stake in shares of Omeros Corporation by 15.2% in the third quarter. Ingalls & Snyder LLC now owns 5,085,949 shares of the biopharmaceutical company’s stock worth $56,759,000 after buying an additional 671,370 shares in the last quarter. Tocqueville Asset Management L.P. boosted its stake in shares of Omeros Corporation by 0.4% in the third quarter. Tocqueville Asset Management L.P. now owns 959,744 shares of the biopharmaceutical company’s stock worth $10,711,000 after buying an additional 3,741 shares in the last quarter. Finally, Capital Fund Management S.A. bought a new stake in shares of Omeros Corporation during the third quarter worth about $245,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.
Shares of Omeros Corporation (NASDAQ:OMER) traded down 2.05% on Tuesday, reaching $12.45. The company’s stock had a trading volume of 332,396 shares. Omeros Corporation has a 52-week low of $7.20 and a 52-week high of $16.80. The stock’s market cap is $534.29 million. The firm’s 50 day moving average is $9.97 and its 200-day moving average is $10.88.
Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.06. The firm earned $11.30 million during the quarter, compared to analyst estimates of $11.64 million. During the same period last year, the business posted ($0.53) EPS. The company’s revenue was up 253.1% on a year-over-year basis. On average, equities research analysts forecast that Omeros Corporation will post ($1.69) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “American Financial Group Inc. Maintains Position in Omeros Corporation (OMER)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/29/american-financial-group-inc-maintains-position-in-omeros-corporation-omer.html.
A number of equities research analysts have recently issued reports on the company. Wedbush dropped their price objective on Omeros Corporation from $56.00 to $47.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 16th. Zacks Investment Research cut Omeros Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, November 16th. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price objective on shares of Omeros Corporation in a research note on Wednesday, August 10th. Maxim Group decreased their target price on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, August 10th. Finally, WBB Securities reissued a “buy” rating and set a $75.00 target price on shares of Omeros Corporation in a report on Thursday, November 17th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $33.23.
In other news, VP Marcia S. Kelbon sold 16,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the transaction, the vice president now owns 179,597 shares in the company, valued at $1,959,403.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.60% of the stock is owned by insiders.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.